A Comparison of Effects of Standard Dose vs. Low Dose Advagraf With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Trial Profile

A Comparison of Effects of Standard Dose vs. Low Dose Advagraf With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Corticosteroids; Irbesartan; Mycophenolate mofetil; Ramipril
  • Indications Kidney disorders; Renal transplant rejection
  • Focus Adverse reactions; Registrational
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 11 Jul 2017 Planned primary completion date changed from 1 Dec 2015 to 11 May 2015.
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top